Long-term Follow-up Study of BRL-101 for TDT

Not yet recruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

December 8, 2024

Primary Completion Date

August 20, 2038

Study Completion Date

October 15, 2038

Conditions
Thalassemia, Beta
Interventions
OTHER

Assessments

Safety and efficacy assessments

Trial Locations (7)

300000

Tianjin Institute of Hematology, Tianjin

510006

Nanfang Hospital, Southern Medical University, Guangzhou

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou

Shenzhen Children 's Hospital, Shenzhen

510510

Xiangya Hospital of Central South University, Changsha

530021

No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital, Nanning

The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY, Guangxi

Sponsors
All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Xiangya Hospital of Central South University

OTHER

collaborator

Chinese Academy of Medical Sciences

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

OTHER

collaborator

Shenzhen Children 's Hospital

UNKNOWN

lead

Bioray Laboratories

INDUSTRY

NCT06298630 - Long-term Follow-up Study of BRL-101 for TDT | Biotech Hunter | Biotech Hunter